There is an increasing momentum in research and pharmaceutical industry communities to
design sustained, non-invasive delivery systems to treat chronic neovascular ocular …

Delivery of pharmaceuticals to the posterior segment presents challenges that arise from the
anatomy and clearance pharmacokinetics of the eye. Systemic and several local …

Introduction: Treating posterior eye diseases has become a major area of focus for
pharmaceutical and biotechnology companies. Current standard of care for treating …

Diabetic macular edema (DME) secondary to diabetic retinopathy (DR) is a major cause for
functional visual loss in the developed world. Laser photocoagulation has been used for …

Introduction: Age-related macular degeneration (AMD) is the leading cause of vision loss
among the elderly. Atrophic AMD, including early, intermediate and geographic atrophy …

Purpose. In order to improve the drug availability after intravitreal administration, solid lipid
nanoparticles (SLNs) containing diclofenac were prepared. Methods. In this experimental …

Corticosteroid use has been found as a risk factor for ocular hypertension and glaucoma
since 1950s. The effect of corticosteroids on intraocular pressure varies depending on their …

Introduction: During the past decade, there have been significant advances in the
pharmacotherapies for the treatment of diabetic macular edema (DME). Among the presently …

Uveitis is often chronic and potentially sight-threatening disorder and because of the chronic
nature of the inflammation and associated risks of complications, the treatment of uveitis …

Purpose. In order to improve the drug availability after intravitreal administration, solid lipid
nanoparticles (SLNs) containing diclofenac were prepared. Methods. In this experimental …